合肥美亚光电技术股份有限公司 关于回购注销部分已授予限制性股票减资 暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 证券代码：002690 证券简称：美亚光电 公告编号：2025-031 除上述文件外，还需携带法定代表人授权委托书和代理人有效身份证的原件及 复印件。债权人为自然人的，需同时携带有效身份证的原件及复印件；委托他 人申报的，除上述文件外，还需携带授权委托书和代理人有效身份证件的原件 及复印件。 债权申报具体方式如下： 1、债权申报登记地点：安徽省合肥市高新技术产业开发区望江西路668号 公司证券部 2、申报时间：2025年11月13日-2025年12月27日工作日 9:00-17:00 3、联系人：公司证券部 4、联系电话：0551-65305898 合肥美亚光电技术股份有限公司（以下简称"公司"）第五届董事会第十 六次会议、第五届监事会第十五次会议以及2025年第一次临时股东会，分别审 议通过了《关于回购注销部分限制性股票的议案》。 鉴于预留授予的激励对象中共有6名激励对象已离职，不再具备激励对象资 格，根据《公司2021年限制性 ...

法律意见书 致：合肥美亚光电技术股份有限公司 安徽天禾律师事务所 关于合肥美亚光电技术股份有限公司 2025 年第一次临时股东会的法律意见书 天律意 2025 第 02971 号 本所根据《证券法》的要求，按照律师行业公认的业务标准、道德规范和勤 勉尽责精神对本次股东会相关事项进行了见证，现对本次股东会的召集、召开及 其他相关事项发表如下意见： 一、关于本次股东会的召集、召开程序 根据《中华人民共和国公司法》(下称"《公司法》")、《中华人民共和国 证券法》（下称"《证券法》"）、《上市公司股东会规则》和《合肥美亚光电 技术股份有限公司章程》（下称"《公司章程》"）的有关规定，安徽天禾律师 事务所接受合肥美亚光电技术股份有限公司（下称"公司"）的委托，指派本所 李军、陈策律师出席公司 2025 年第一次临时股东会（下称"本次股东会"）， 并对本次股东会相关事项进行见证，出具法律意见。 本所同意将本法律意见书作为本次股东会的公告文件，随公司其他文件一并 报送有关主管部门审查并予以公告。 （一）经查验，公司董事会于 2025 年 10 月 25 日以公告方式在《证券时报》 和巨潮资讯网（http://www.cn ...

证券代码：002690 证券简称：美亚光电 公告编号：2025-032 合肥美亚光电技术股份有限公司 倪迎久先生符合《公司法》《公司章程》规定的关于董事任职的资格和条 件。本次选举完成后，公司第五届董事会中兼任公司高级管理人员及由职工代 表担任董事的人数总计不超过公司董事总数的二分之一，符合相关法律法规的 要求。 二、备查文件 1、公司职工代表大会决议。 特此公告。 合肥美亚光电技术股份有限公司董事会 2025年11月13日 关于选举职工代表董事的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、选举情况 根据《中华人民共和国公司法》《上市公司章程指引》的相关要求和规定， 合肥美亚光电技术股份有限公司（以下简称"公司"）于2025年11月12日召开 2025年第一次临时股东会，审议通过了《关于取消监事会并修订<公司章程>的 议案》。根据修订后的《合肥美亚光电技术股份有限公司章程》，公司董事会设 职工代表董事一名，由职工代表大会民主选举产生。 公司于2025年11月12日召开职工代表大会，选举倪迎久先生（简历见附 件）为公司第五届董事会职工代表董事，任期自本 ...

Group 1 - On November 11, a total of 2 listed companies will have their restricted shares unlocked, with a total market value of approximately 140 million yuan [1] - The specific details of the restricted share unlocks are as follows: China Chemical (stock code: 601117) will unlock 19.7868 million shares under equity incentive restrictions, while Meiya Optoelectronics (stock code: 002690) will unlock 346,800 shares under equity incentive restrictions [1]

Core Points - The company, Meiya Optoelectronics, announced the completion of the second unlock period for its 2021 restricted stock incentive plan, allowing for the release of shares [1] - A total of 286 eligible participants will have 327,350 shares unlocked, which represents 0.0371% of the company's latest total share capital [1] - The unlocked shares will be available for trading starting from November 11, 2025 [1]

证券代码：002690 证券简称：美亚光电 公告编号：2025-029 合肥美亚光电技术股份有限公司 关于2021年限制性股票激励计划预留授予部分第二个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、公司 2021 年限制性股票激励计划预留授予部分第二个解除限售期解除限 售条件已经成就，符合解除限售条件的激励对象共计 286 名，可解除限售的限制 性股票数量为 32.735 万股，占公司最新总股本的 0.0371%。 2、本次解除限售股份可上市流通的日期为：2025 年 11 月 11 日。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）及公司 《2021年限制性股票激励计划（草案修订稿）》（以下简称"《激励计划（草案 修订稿）》"）的相关规定，公司办理了本次股权激励计划预留授予部分第二个 解除限售期涉及的股份上市流通手续，符合解除限售条件的286名激励对象共计 可解除限售32.735万股限制性股票。现将有关事项说明如下： 1、2021 年 10 月 31 日，公司第四届董事会第九次会议审 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [5][12]. Core Insights - The company reported a revenue of 1.694 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 7.35%. The net profit attributable to shareholders was 519 million yuan, up 15.30% year-on-year [1][2]. - In Q3 alone, the company achieved a revenue of 671 million yuan, a 3.67% increase year-on-year, with net profit attributable to shareholders reaching 216 million yuan, reflecting a 21.33% year-on-year growth [1][2]. - The company has seen a significant increase in contract liabilities, which grew by 137.09% compared to the end of 2024, primarily due to an increase in advance payments, laying a solid foundation for future performance [2]. Financial Performance - The gross margin and net margin for the first three quarters of 2025 were 52.95% and 30.63%, respectively, both showing improvements of 2.50 and 2.11 percentage points year-on-year [3]. - The company maintained stable expense ratios, with sales, management, and financial expense ratios at 11.22%, 3.85%, and -1.48%, respectively [3]. - Research and development expense ratio increased to 6.55%, up 0.55 percentage points year-on-year, indicating a commitment to innovation [3]. Innovation and Market Position - The company has launched several new products and technologies in the color sorting machine and high-end medical imaging equipment sectors, reinforcing its market leadership [4]. - The introduction of the AI-powered color sorting machine and a comprehensive digital processing solution for rice signifies the company's transition towards integrated smart diagnostic solutions [4]. Investment Recommendations and Profit Forecast - The company is expected to achieve revenues of 2.596 billion, 2.899 billion, and 3.219 billion yuan for 2025, 2026, and 2027, respectively, with net profits projected at 749 million, 845 million, and 957 million yuan [5][7]. - Earnings per share (EPS) are forecasted to be 0.85, 0.96, and 1.08 yuan for the same years, with corresponding price-to-earnings (P/E) ratios of 23.86, 21.14, and 18.67 [5][7].

Core Points - The Bioeconomy Index (970038) closed at 2277.51 points, down 0.16%, with a trading volume of 18.883 billion yuan and a turnover rate of 1.2% [1] - Among the index constituents, 23 stocks rose while 27 fell, with Iwubio leading the gainers at 6.71% and Meiya Optoelectronics leading the decliners at 3.02% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 225.09 yuan, and a market cap of 272.908 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 116.50 yuan, and a market cap of 47.525 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.97 yuan, and a market cap of 56.849 billion yuan [1] - Other notable constituents include Shishihistory (sz002252), Table Pharmaceutical (sz300347), and Muyuan Foods (sz002714) [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 871 million yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [3] - Key capital flows include: - Iwubio (300357) with a net inflow of 52.9277 million yuan from institutional investors [3] - Dabo Medical (002901) with a net inflow of 31.8434 million yuan from institutional investors [3] - Changchun High-tech (000661) with a net inflow of 27.6452 million yuan from institutional investors [3]

Core Insights - The company reported Q3 2025 results with revenue of 1.694 billion yuan, a year-on-year increase of 7.35%, and a net profit attributable to shareholders of 519 million yuan, up 15.30% year-on-year, exceeding market expectations [1] Group 1: Growth Analysis - In Q3 2025, the company achieved revenue of 671 million yuan, a year-on-year increase of 3.67%, driven by stable growth in color sorting machines and resilience in the medical business despite adverse market conditions [2] - The net profit attributable to shareholders for Q3 2025 was 216 million yuan, reflecting a year-on-year growth of 21.33%, indicating a strategic shift towards enhancing operational quality [2] Group 2: Profitability Analysis - For the first three quarters of 2025, the company reported a gross margin of 52.95%, an increase of 2.50 percentage points year-on-year, attributed to automation upgrades reducing labor costs [3] - The net profit margin was 30.63%, up 2.11 percentage points year-on-year, influenced by fluctuations in foreign exchange losses and a decrease in sales and management expense ratios [3] - R&D expenses accounted for 6.55% of revenue, reflecting a steady increase in investment in innovation [3] Group 3: Operational Efficiency and Cash Flow - Inventory turnover days decreased by 32.44 days to 109.57 days, and accounts receivable turnover days decreased by 20.61 days to 72.27 days, indicating improved sales channel optimization and cost control [3] - The net operating cash flow for the first three quarters was 649 million yuan, a significant year-on-year increase of 34.91%, demonstrating improved cash flow [3] Group 4: R&D Investment - The company invested 111 million yuan in R&D in the first three quarters of 2025, a year-on-year increase of 17.36%, with a total of 175 valid invention patents [4] Group 5: AI Integration in Dental Healthcare - The company launched the "Dental Medical Intelligent Body Matrix" at the 2025 Shanghai DTC International Dental Exhibition, integrating AI, big data, IoT, and cloud computing to enhance clinical and operational efficiency [5] - This initiative aims to address key challenges in dental healthcare, moving from simple tool upgrades to comprehensive smart solutions [5][6] Group 6: Future Outlook - The company maintains a "buy" rating, projecting net profits of 759 million yuan, 888 million yuan, and 1.022 billion yuan for 2025-2027, with respective year-on-year growth rates of 16.85%, 17.11%, and 15.00% [6]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [3][11][14]. Core Insights - The company reported Q3 2025 earnings that exceeded market expectations, with a revenue of 1.694 billion yuan, a year-on-year increase of 7.35%, and a net profit of 519 million yuan, up 15.30% year-on-year [5][11]. - The company is embracing AI technology to enhance its dental medical services, launching the "Dental Medical Intelligent Matrix" which integrates hardware, software, and ecosystem solutions [10][11]. - The company has shown significant improvement in cash flow, with a net operating cash flow of 649 million yuan, a year-on-year increase of 34.91% [9][11]. Financial Performance Summary - For Q3 2025, the company achieved a revenue of 671 million yuan, a 3.67% increase year-on-year, and a net profit of 216 million yuan, reflecting a 21.33% growth [5][7]. - The gross profit margin for the first three quarters of 2025 was 52.95%, an increase of 2.50 percentage points year-on-year, indicating improved operational efficiency [8]. - The company’s R&D investment reached 111 million yuan in the first three quarters of 2025, a 17.36% increase year-on-year, representing 6.55% of total revenue [9][11]. Growth Projections - The company forecasts net profits of 759 million yuan, 888 million yuan, and 1.022 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 16.85%, 17.11%, and 15.00% [11][12]. - Revenue projections for the next few years are 2.674 billion yuan for 2025, 3.039 billion yuan for 2026, and 3.410 billion yuan for 2027, with expected growth rates of 16% and 14% respectively [3][12].